0001655970-16-000002.txt : 20160317 0001655970-16-000002.hdr.sgml : 20160317 20160317111243 ACCESSION NUMBER: 0001655970-16-000002 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20160317 DATE AS OF CHANGE: 20160317 EFFECTIVENESS DATE: 20160317 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Envisia Therapeutics, Inc. CENTRAL INDEX KEY: 0001655970 IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-259444 FILM NUMBER: 161511673 BUSINESS ADDRESS: STREET 1: 419 DAVIS DRIVE STREET 2: SUITE 100 CITY: MORRISVILLE STATE: NC ZIP: 27560 BUSINESS PHONE: 919.973.1440 MAIL ADDRESS: STREET 1: 419 DAVIS DRIVE STREET 2: SUITE 100 CITY: MORRISVILLE STATE: NC ZIP: 27560 D 1 primary_doc.xml X0707 D LIVE 0001655970 Envisia Therapeutics, Inc. 419 DAVIS DRIVE SUITE 100 MORRISVILLE NC NORTH CAROLINA 27560 919.973.1440 DELAWARE Ascendia Therapeutics, Inc. None Corporation true 2013 Ben Yerxa c/o Envisia Therapeutics, Inc. 419 DAVIS DRIVE, SUITE 100 MORRISVILLE NC NORTH CAROLINA 27560 Executive Officer Eric Linsley c/o Envisia Therapeutics, Inc. 419 DAVIS DRIVE, SUITE 100 MORRISVILLE NC NORTH CAROLINA 27560 Executive Officer Neal Fowler c/o Envisia Therapeutics, Inc. 419 DAVIS DRIVE, SUITE 100 MORRISVILLE NC NORTH CAROLINA 27560 Director Stephen Bloch c/o Envisia Therapeutics, Inc. 419 DAVIS DRIVE, SUITE 100 MORRISVILLE NC NORTH CAROLINA 27560 Director Ed Mathers c/o Envisia Therapeutics, Inc. 419 DAVIS DRIVE, SUITE 100 MORRISVILLE NC NORTH CAROLINA 27560 Director Adrienne Graves c/o Envisia Therapeutics, Inc. 419 DAVIS DRIVE, SUITE 100 MORRISVILLE NC NORTH CAROLINA 27560 Director Gary Phillips c/o Envisia Therapeutics, Inc. 419 DAVIS DRIVE, SUITE 100 MORRISVILLE NC NORTH CAROLINA 27560 Director William Yelle c/o Envisia Therapeutics, Inc. 419 DAVIS DRIVE, SUITE 100 MORRISVILLE NC NORTH CAROLINA 27560 Director Biotechnology Decline to Disclose 06b false 2016-03-11 false true true true true Offer and sale of Series A Preferred Stock and Warrants to purchase Series A Preferred Stock, and the underlying shares of common stock issuable upon conversion thereof. false 0 16547948 10117521 6430427 Total amount sold includes the value of cancelled indebtedness formerly held by certain purchasers in the aggregate principal amount of $4,944,000. false 9 0 0 500000 true false Envisia Therapeutics, Inc. /s/ Eric Linsley Eric Linsley Chief Financial Officer & Treasurer 2016-03-17